3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro

FASEB Journal

Volumn 20, Issue 14, 2006, Pages 2496-2511

  Zhang, Wei ^a,b   Shin, Eun Joo ^c   Wang, Tongguang ^a   Phil, Ho Lee ^c   Pang, Hao ^a   Wie, Myung Bok ^c   Kim, Won Ki ^c,d   Kim, Seong Jin ^e   Huang, Wen Hsin ^f   Wang, Yongjun ^b   Zhang, Wanqin ^g   Hong, Jau Shyong ^a   Kim, Hyoung Chun ^c  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c Kangwon National University   (South Korea)

^d Ewha Womans University   (South Korea)

^e NATIONAL CANCER INSTITUTE   (United States)

^f NATIONAL DEFENSE UNIVERSITY   (Taiwan)

^g DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Astroglia; Microglia; Neurotrophic factors; PD; ROS; Striatum; Substantia nigra pars compacta (SNpc)

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 17 ALLYLOXY 17 METHYLMORPHINAN; 3 CYCLOPROPYLMETHOXY 17 METHYLMORPHINAN; 3 METHYL N METHYLMORPHINAN; DEXTROMETHORPHAN; DEXTRORPHAN; HISTONE H3; LIPOPOLYSACCHARIDE; MORPHINAN DERIVATIVE; NORLEVORPHANOL; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROGLIA; MOTOR ACTIVITY; MOUSE; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ASTROCYTES; BEHAVIOR, ANIMAL; DEXTROMETHORPHAN; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MOLECULAR STRUCTURE; PARKINSON DISEASE; PARKINSONIAN DISORDERS; RATS; REACTIVE OXYGEN SPECIES; SUBSTANTIA NIGRA;

EID: 33845603005     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.06-6006com     Document Type: Article

References (66)

1. Olanow, C. W., and Tatton, W. G. (1999) Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22, 123-144
2. Liu, Y., Qin, L., Li, G., Zhang, W., An, L., Liu, B., and Hong, J. S. (2003) Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J. Pharmacol. Exp. Ther. 305, 212-218
3. Zhang, W., Wang, T., Qin, L., Gao, H. M., Wilson, B., Ali, S. F., Zhang, W., Hong, J. S., and Liu, B. (2004) Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. FASEB J. 18, 589-591
4. Zhang, W., Qin, L., Wang, T., Wei, S. J., Gao, H. M., Liu, J., Wilson, B., Liu, B., Zhang, W., Kim, H. C., and Hong, J. S. (2005) 3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity. FASEB J. 19, 395-397
5. Kim, H. C., Nabeshima, T., Jhoo, W. K., Ko, K. H., Kim, W. K., Shin, E. J., Cho, M., and Lee, P. H. (2001) Anticonvulsant effects of new morphinan derivatives. Bioorg. Med. Chem. Lett. 11, 1651-1654
6. Kim, H. C., Shin, C. Y., Seo, D. O., Jhoo, J. H., Jhoo, W. K., Kim, W. K., Shin, E. J., Lee, Y. H., Lee, P. H., and Ko, K. H. (2003) New morphinan derivatives with negligible psychotropic effects attenuate convulsions induced by maximal electroshock in mice. Life Sci. 72, 1883-1895
7. Shin, E. J., Nah, S. Y., Kim, W. K., Ko, K. H., Jhoo, W. K., Lim, Y. K., Cha, J. Y., Chen, C. F., and Kim, H. C. (2005) The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan. Br. J. Pharmacol. 144, 908-918
8. Hows, M. E. P., Ashmeade, T. E., Billinton, A., Perren, M. J., Austin. A. A., Virley, D. J., Organ, A. J., and Shah, A. J. (2004) High-performance liquid hromatography/tandem mass spectrometry assay for the determination of 1-methyl-4-phenyl pyridinium (MPP+) in brain tissue homogenates. J. Neurosci. Methods 137, 221-226
9. Kim, H.C, Jhoo, W.K, Shin, E. J., and Bing, G. (2000) Selenium deficiency potentiates methamphetamine-induced nigral neuronal loss; comparison with MPTP model. Brain Res. 862, 247-252
10. Ali, S. F., Newport, G. D., Holson, R. R., Slikker, W., Jr., and Bowyer, J. F. (1994) Low environmental temperatures or pharmacologic agents that produce hypothermia decrease methamphetamine neurotoxicity in mice. Brain Res. 658, 33-38
11. Wang, T., Pei, Z., Zhang, W., Liu, B., Langenbach, R., Lee, C., Wilson, B., Reece, J. M., Miller, D. S., and Hong, J. S. (2005) MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration. FASEB J. 19, 1134-1136
12. Liu, B., Du, L., and Hong, J. S. (2000) Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J. Pharmacol. Exp. Ther. 293, 607-617
13. Zhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J. S., and Zhang, J. (2005) Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 19, 533-542
14. Liu, J., He, Y. Y., Chignell, C. F., Clark, J., Myers, P., Saavedra, J. E., and Waalkes, M. P. (2005) Limited protective role of V-PYRRO/NO against cholestasis produced by alpha-naphthylisothiocyanate in mice. Biochem. Pharmacol. 70, 144-151
15. Tan, A. S., and Berridge, M. V. (2000) Superoxide produced by activated neutrophils efficiently reduces the tetrazolium salt, WST-1 to produce a soluble formazan: a simple colorimetric assay for measuring respiratory burst activation and for screening anti-inflammatory agents. J. Immunol. Methods 238, 59-68
16. Peskin, A. V., and Winterbourn, C. C. (2000) A microtiter plate assay for superoxide dismutase using a water-soluble tetrazolium salt (WST-1). Clin. Chim. Acta 293, 157-166
17. Liu, Y., Qin, L., Wilson, B. C., An, L., Hong, J. S., and Liu, B. (2002) Inhibition by naloxone stereoisomers of beta-amyloid peptide (1-42) -induced superoxide production in microglia and degeneration of cortical and mesencephalic neurons. J. Pharmacol. Exp. Ther. 302, 1212-1219
18. Rosenkranz, A. R., Schmaldienst, S., Stuhlmeier, K. M., Chen, W., Knapp, W., and Zlabinger, G. J. (1992) A microplate assay for the detection of oxidative products using 2′,7′-dichlorofluorescin-diacetate. J. Immunol. Methods 156, 39-45
19. Wang, T., Liu, B., Zhang, W., Wilson, B., and Hong, J. S. (2004) Andrographolide reduces inflammation-mediated dopaminergic neurodegeneration in mesencephalic neuron-glia cultures by inhibiting microglial activation. J. Pharmacol. Exp. Ther. 308, 975-983
20. Gao, H. M., Liu, B., Zhang, W., and Hong, J. S. (2003) Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J. 17, 1954-1956
21. Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D. K., Ischiropoulos, H., and Przedborski, S. (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22, 1763-1771
22. Zhang, W., Wang, T., Qin, L., Gao, H. M., Wilson, B., Ali, S. F., Hong, J. S., and Liu, B. (2004) Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. FASEB J. 18, 589-559
23. Eberhardt, O., Coelln, R. V., Kugleret, S., Lindenau, J., Rathke-Hartlieb, S., Gerhardt, E., Haid, S., Isenmann, S., Gravel, C., Srinivasan, A., et al. 2000) Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine model of Parkinson's disease. J. Neurosci. 20, 9126-9134
24. Cleren, C., Calingasan, N. Y., Chen, J., and Beal, M. F. (2005) Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity. J. Neurochem. 94, 995-1004
25. Zhou, H. F., Liu, X. Y., Niu, D. B., Li, F. Q., He, Q. H., and Wang, X. M. (2005) Triptolide protects dopaminergic neurons from inflammation-mediated damage induced by lipopolysaccharide intranigral injection. Neurobiol. Dis. 18, 441-449
26. Li, F. Q., Cheng, X. X., Liang, X. B., Wang, X. H., Xue, B., He, Q. H., Wang, X. M., and Han, J. S. (2003) Neurotrophic and neuroprotective effects of tripchlorolide, an extract of Chinese herb Tripterygium wilfordii Hook F, on dopaminergic neurons. Exp. Neurol. 179, 28-37
27. Yasuhara, T., Shingo, T., Muraoka, K., Kameda, M., Agari, T., Wen Ji, Y., Hayase, H., Hamada, H., Borlongan, C. V., and Date, I. (2005) Neurorescue effects of VEGF on a rat model of Parkinson's disease. Brain Res. 1053, 10-18
28. Peng, J., Stevenson, F. F., Doctrow, S. R., and Andersen, J. K. (2005) Superoxide dismutase/catalase mimetics are neuroprotective against selective paraquat-mediated dopaminergic neuron death in the substantial nigra: implications for Parkinson disease. J. Biol. Chem. 280, 29194-29198
29. Inden, M., Kondo, J., Kitamura, Y., Takata, K., Nishimura, K., Taniguchi, T., Sawada, H., and Shimohama, S. (2005) Proteasome inhibitors protect against degeneration of nigral dopaminergic neurons in hemiparkinsonian rats. J. Pharmacol. Sci. 97, 203-211
30. Datla, K. P., Bennett, R. D., Zbarsky, V., Ke, B., Liang, Y. F., Higa, T., Bahorun, T., Aruoma, O. I., and Dexter, D. T. (2004) The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease. J. Pharm. Pharmacol. 56, 649-654
31. Cutillas, B., Ambrosio, S., and Unzeta, M. (2002) Neuroprotective effect of the monoamine oxidase inhibitor PF 9601N [N-(2-propynyl)-2-(5-benzyloxy- indolyl) methylamine] on rat nigral neurons after 6-hydroxydopamine-striatal lesion. Neurosci. Lett. 329, 165-168
32. Roussa, E., Farkas, L. M., and Krieglstein, K. (2004) TGF-beta promotes survival on mesencephalic dopaminergic neurons in cooperation with Shh and FGF-8. Neurobiol. Dis. 16, 300-310
33. Wood, T. K., McDermott, K. W., and Sullivan, A. M. (2005) Differential effects of growth/differentiation factor 5 and glial cell line-derived neurotrophic factor on dopaminergic neurons and astroglia in cultures of embryonic rat midbrain. J. Neurosci. Res. 80, 759-766
34. Erickson, J. T., Brosenitsch, T. A., and Katz, D. M. (2001) Brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor are required simultaneously for survival of dopaminergic primary sensory neurons in vivo. J. Neurosci. 21, 581-589
35. Krieglstein, K., Strelau, J., Schober, A., Sullivan, A., and Unsicker, K. (2002) TGF-beta and the regulation of neuron survival and death. J. Physiol. (Paris) 96, 25-30
36. Jeong, M. R., Hashimoto, R., Senatorov, V. V., Fujimaki, K., Ren, M., Lee, M. S., and Chuang, D. M. (2003) Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition. FEBS Lett. 542, 74-78
37. Tunnicliff, G. (1999) Actions of sodium valproate on the central nervous system. J. Physiol. Pharmacol. 50, 347-365
38. Gottlicher, M., Minucci, S., Zhu, P., Kramer, O. H., Schimpf, A., Giavara, S., Sleeman, J. P., Lo Coco, F., Nervi, C., Pelicci, P. G., and Heinzel, T. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20, 6969-6978
39. Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., and Klein, P. S. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276, 36734-36741
40. Chang, K. T., and Min, K. T. (2002) Regulation of lifespan by histone deacetylase. Ageing Res. Rev. 1, 313-326
41. De Sarno, P., Li, X., and Jope, R. S. (2002) Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43, 1158-1164
42. Gao, H. M., Liu, B., Zhang, W., and Hong, J. S. (2003) Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. FASEB J. 17, 1957-1959
43. McGeer, P. L., Schwab, C., Parent, A., and Doudet, D. (2003) Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine administration. Ann. Neurol. 54, 599-604
44. Feng, Z. H., Wang, T. G., Li, D. D., Fung, P., Wilson, B. C., Liu, B., Ali, S. F., Langenbach, R., and Hong, J. S. (2002) Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci. Lett. 329, 354-358
45. Wu, D. C., Teismann, P., Tieu, K., Vila, M., Jackson-Lewis, V., Ischiropoulos, H., and Przedborski, S. (2003) NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 100, 6145-6150
46. Teismann, P., Vila, M., Choi, D. K., Tieu, K., Wu, D. C., Jackson-Lewis, V., and Przedborski, S. (2003) COX-2 and neurodegeneration in Parkinson's disease. Ann. N. Y. Acad. Sci. 991, 272-277
47. Sriram, K., Matheson, J. M., Benkovic, S. A., Miller, D. B., Luster, M. I., and O'Callaghan, J. P. (2002) Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J. 16, 1474-1476
48. Liu, B., Gao, H. M., and Hong, J. S. (2003) Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ. Health Perspect. 111, 1065-1073
49. Block, M. L., and Hong, J. S. (2005) Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 76, 77-98
50. Liu, B., and Hong, J. S. (2003) Role of microglia in inflammation- mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. 304, 1-7
51. Blum, M. (1998) A null mutation in TGF-alpha leads to a reduction in midbrain dopaminergic neurons in the substantia nigra. Nat. Neurosci. 1, 374-377
52. Jaumotte, J. D., and Zigmond, M. J. (2005) Dopaminergic innervation of forebrain by ventral mesencephalon in organotypic slice co-cultures: effects of GDNF. Brain Res. Mol. 134, 139-146
53. Roussa, E., and Krieglstein, K. (2004) GDNF promotes neuronal differentiation and dopaminergic development of mouse mesencephalic neurospheres. Neurosci. Lett. 361, 52-55
54. Sun, Z. H., Lai, Y. L., Li, P., Zuo, H. C., and Xie, Z. P. (2004) GDNF augments survival and differentiation of TH-positive neurons in neural progenitor cells. Cell Biol. Int. 28, 323-325
55. Chen, Y., Ai, Y., Slevin, J. R., Maley, B. E., and Gash, D. M. (2005) Progenitor proliferation in the adult hippocampus and substantia nigra induced by glial cell line-derived neurotrophic factor. Exp. Neurol. 196, 87-95
56. Kobori, N., Waymire, J. C., Haycock, J. W., Clifton, G. L., and Dash, P. K. (2004) Enhancement of tyrosine hydroxylase phosphorylation and activity by glial cell line-derived neurotrophic factor. J. Biol. Chem. 279, 2182-2191
57. Brizard, M., Carcenac, C., Bemelmans, A. P., Feuerstein, C., Mallet, J., and Savasta, M. (2005) Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease. Neurobiol. Dis.
58. Muller, H. W., Junghans, U., and Kappler, J. (1995) Astroglial neurotrophic and neurite-promoting factors. Pharmacol. Ther. 65, 1-18
59. Canudas, A. M., Pezzi, S., Canals, J. M., Pallas, M., and Alberch, J. (2005) Endogenous brain-derived neurotrophic factor protects dopaminergic nigral neurons against transneuronal degeneration induced by striatal excitotoxic injury. Brain Res. Mol. 134, 147-154
60. Urbanics, R. (2001) NT-3. Takeda/Regeneron/Amgen. IDrugs 4, 820-824
61. Farkas, L. M., Dunker, N., Roussa, E., Unsicker, K., and Krieglstein, K. (2003) Transforming growth factor-beta(s) are essential for the development of midbrain dopaminergic neurons in vitro and in vivo. J. Neurosci. 23, 5178-5186
62. Gao, H. M., Jiang, J., Wilson, B., Zhang, W., Hong, J. S., and Liu, B. (2002) Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J. Neurochem. 81, 1285-1297
63. Qin, L., Liu, Y., Wang, T., Wei, S. J., Block, M. L., Wilson, B., Liu, B., and Hong, J. S. (2004) NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J. Biol. Chem. 279, 1415-1421
64. Qin, L., Liu, Y., Cooper, C., Liu, B., Wilson, B., and Hong, J. S. (2002) Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J. Neurochem. 83, 973-983
65. Basu, A., Krady, J. K., O'Malley, M., Styren, S. D., DeKosky, S. T., and Levison, S. W. (2002) The type 1 interleukin-1 receptor is essential for the efficient activation of microglia and the induction of multiple proinflammatory mediators in response to brain injury. J. Neurosci. 22, 6071-6082
66. Gao, H. M., Hong, J. S., Zhang, W., and Liu, B. (2002) Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J. Neurosci. 22, 782-790